Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

The best of times, the worst of times for psychiatric disease

As long-awaited advances in psychiatric genetics begin to materialize in force, promising to steer us safely to the best of times in psychiatric disease research, many pharmaceutical companies pull away from the challenge of drug development, threatening to bring us to the worst of times for the field. There is a real danger of missed opportunities and a sense of urgency for defining a clear path forward.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


Support from the US National Institutes of Health (grant 5R13MH091947 to M.K.) and the Martinos family is gratefully acknowledged.

Author information

Authors and Affiliations



Corresponding author

Correspondence to Maria Karayiorgou.

Ethics declarations

Competing interests

Edward Bullmore is employed half-time by University of Cambridge and half-time by GlaxoSmithKline and is a stockholder in GlaxoSmithKline.

Additional information

A complete list of authors and affiliations appears at the end of this paper.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karayiorgou, M., Flint, J., Gogos, J. et al. The best of times, the worst of times for psychiatric disease. Nat Neurosci 15, 811–812 (2012).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research